Natera earns FDA breakthrough designation as Natera stock trades at EUR 360.20

Published on 10/12/2026 at 11:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FDA reviewed Natera's test across 12 cancer types. Natera stock costs EUR 360.20 on October 12, 2026 versus the Xetra close of EUR 356.80 on October 9, 2026.

Key points in brief

Natera received FDA Breakthrough Device designation for its multi-cancer early detection assay on October 9, 2026.
The FDA assessed data spanning 12 cancer types, while the designation does not authorize marketing approval.
Second-quarter 2026 revenue was USD 752.75 million, up 37.70 percent year over year, with a USD 0.47 adjusted loss per share.
Natera stock was EUR 360.20 at Lang & Schwarz on October 12, 2026, plus 0.95 percent versus the Xetra close of EUR 356.80.

NTRA, US6323071042, Illustration mit AI erstellt.

Natera stock (ISIN US6323071042) was trading at EUR 360.20 at Lang & Schwarz on October 12, 2026 at 11:30 a.m. CEST, plus 0.95 percent versus the Xetra close of EUR 356.80 on October 9, 2026. According to Natera on October 9, 2026, the U.S. Food and Drug Administration granted Breakthrough Device designation to its multi-cancer early detection assay after reviewing data from 12 cancer types.

Three milestones shape the story

The chronology shows how quickly Natera's oncology narrative has developed. On August 6, 2026, Natera reported second-quarter revenue of USD 752.75 million and an adjusted loss of USD 0.47 per share, according to MarketBeat. On October 6, 2026, Natera reported Signatera study results showing 100.00 percent sensitivity and 97.00 percent specificity. The current October 9 designation adds a regulatory milestone tied to data from 12 cancer types.

What does the designation change?

The designation gives Natera access to an accelerated FDA development and review framework, but it is not marketing approval. Yahoo Finance reported on October 9, 2026, that the assay remains under development and still requires further evidence before any clinical authorization. That distinction matters because the FDA reviewed performance across 12 cancer types, while the release supplied no marketing timetable.

Results support the valuation debate

The latest operating figures provide the counterweight to the regulatory headline. Second-quarter 2026 revenue of USD 752.75 million was 37.70 percent higher than in the same quarter of 2025, while the USD 0.47 adjusted loss per share was narrower than the USD 0.49 consensus loss, according to MarketBeat. The same report put the average 12-month analyst target at USD 353.45 and the consensus at 16 buy, two strong-buy, four hold and one sell ratings. The target is below the reported USD 400.71 opening price cited by the source, making execution and regulatory conversion central to the valuation discussion.

Next reporting date

ToAlpha lists November 5, 2026 as Natera's next earnings date. The appointment would give investors the next scheduled checkpoint for revenue growth, losses and progress on the early detection program.

Stock stays below its yearly high

Natera had a USD 57.76 billion market capitalization and a USD 167.99 to USD 437.41 52-week range in the October 10, 2026 MarketBeat snapshot. The Lang & Schwarz price of EUR 360.20 on October 12, 2026 stood EUR 3.40, or 0.95 percent, above the Xetra close of EUR 356.80 on October 9, 2026. The further course of trading is shown by the continuously updated real-time quote of Natera stock.